Cyclic Peptide Self-Assembly for Antimicrobial Extracellular Matrices
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing synthetic extracellular matrices have limitations such as spanning only nanometre to micrometre dimensions, lacking continuous networks, being toxic, and not being antimicrobial, which restricts their ability to support cell growth and prevent biofilm formation effectively.
Innovation Solution
A cyclic peptide that self-assembles into microscopic fibrillar nets with a specific domain arrangement, forming a synthetic protein network that supports mammalian cell growth and prevents biofilm formation by creating a biologically differential extracellular matrix.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Length of stationary object
If existing synthetic extracellular matrices are used, then nanometre to micrometre dimensional structures are formed, but they cannot support cell growth across larger length scales
Solution Approach 1:
The cyclic peptide is divided into two functional domains (first domain with cationic-anionic-cationic pattern, second domain with anionic-cationic-anionic pattern) that self-assemble into fibrillar structures. These segmented domains create a hierarchical network architecture spanning from nanometre-scale fibrils to micrometre-scale continuous networks, enabling both structural control and biological functionality across multiple length scales
Solution Approach 2:
The patent creates a nested hierarchical structure where nanometre-scale fibrillar assemblies are organized into micrometre-scale continuous networks. The cyclic peptides nest within fibrils, which nest within larger network structures, forming a multi-scale architecture that simultaneously provides nanometre-level structural precision and micrometre-level continuity for cell growth support
2Shape
If existing synthetic extracellular matrices are used, then individual protein fibrils are formed, but they are not physically connected into continuous networks
Solution Approach 1:
The patent merges individual fibrillar structures into continuous networks through the self-assembling cyclic peptide system. The two-domain design enables fibrils to connect and form uninterrupted networks spanning micrometre scales, combining the structural benefits of organized fibrils with the stability of continuous networks for reliable cell growth support
3Ease of manufacture
If existing synthetic extracellular matrices are used, then they are toxic to cells and tissues
Solution Approach 1:
The patent changes the chemical and structural parameters of synthetic matrices by using specifically designed cyclic peptides with balanced cationic and anionic domains. This parameter optimization reduces toxicity while maintaining synthetic manufacturability, creating biocompatible materials that support cell growth without harmful effects
4Reliability
If existing synthetic extracellular matrices are used, then they lack antimicrobial properties
Solution Approach 1:
The cyclic peptide system performs multiple functions simultaneously: it forms structural fibrillar networks for cell support, provides biocompatibility to reduce toxicity, and exhibits antimicrobial activity to prevent biofilm formation. This multi-functional design integrates structural, biological, and protective functions into a single synthetic matrix system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide network enables efficient cell adhesion, proliferation, and resistance to biofilm formation across sub-millimetre dimensions, providing a biologically functional and antimicrobial substrate for tissue engineering and biomedical applications.
Implementation Method 1
The cyclic peptide, which may also be termed a miniprotein, is able to self-assemble into microscopic fibrillar nets
Data Source
Figure 1
Figure 2
Figure 3a~3d
AI summary
A cyclic peptide (10) includes two domains (D1,D2), each including three charged sub-domains (14, 16). The first domain (D1 ) includes two anionic sub-domains (14) followed by a cationic sub-domain (16). The second domain (D2) includes two cationic sub-domains (16) followed by an anionic sub-domain (14). The two domains are connected to one another and separated by a tri-glycyl linker (12). The cyclic peptide (10) is able to self-assemble into a network able to mimic an extracelluar matrix, and which promotes cell growth whilst resisting biofilm formation.